Loading…
The clearance was issued on March 13, 2025.
Lifeward Ltd. (Nasdaq: LFWD) announced that the U.S. Food and Drug Administration (FDA) has issued clearance for its ReWalk 7 exoskeleton. The clearance was granted on March 13, 2025.
The ReWalk 7 exoskeleton is designed to assist individuals with spinal cord injuries in regaining mobility. This clearance allows Lifeward to market and sell the device in the United States.
Lifeward Ltd. has a free float of 17,469,500 shares and 18,293,800 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.